BiancaDeniseSantomassoMD

PubMed

• Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma.
  Xavier Deschênes-Simard, Martina Pennisi, Miguel-Angel Perales, Gunjan L Shah, Andrew D Zelenetz
  Leukemia & Lymphoma. 2025-03-01
• EEG features and synek scale indicate severity of neurotoxicity in adult patients treated with CD19 CAR T-cell therapy.
  David Mao, Anne S Reiner, Xi Chen, Jae Park, Martina Pennisi
  Scientific Reports. 2024-11-23
• 2 citations
  Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy.
  Xavier Deschênes-Simard, Bianca D Santomasso, Parastoo B Dahi
  Blood. 2024-11-14

Abstracts/Posters

• Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells
  Bianca Santomasso, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  Bianca Santomasso, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
  Bianca Santomasso, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management
  Bianca Santomasso, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Neurotoxicity From CAR T-Cell Therapy: Why It Happens, How to Manage It, and Who Is at Risk? 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
• Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018